Dovitinib (TKI-258)

Cat. No.: OB0225WX-2385

Appearance: Solid

Purity: ≥99%

Identity: Confirmed by NMR, and HPLC.

Size:

INQUIRY Datasheet MSDS

Add to basket

Product Overview

Description: Dovitinib is a multi-targeted receptor tyrosine kinase (RTK) inhibitor with high potency against Class III (FLT3/c-Kit, IC50: 1-2 nM), Class IV (FGFR1/3), and Class V (VEGFR1-4) kinases.

Synonym: CHIR-258; 405169-16-6; TKI-258; 4-Amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; Dovitinib (TKI-258, CHIR-258); Dovitinib lactate; TKI258; MFCD10565680; 2(1H)-Quinolinone,4-amino-5-fluoro-3-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-; 4-Amino-5-Fluoro-3-(6-(4-Methylpiperazin-1-yl)-1H-Benzo[D]Imidazol-2-yl)Quinolin-2(1H)-One; 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)quinolin-2(1H)-one; CHIR258; Dovitinib, Free Base; 38O; 4-Amino-5-fluoro-3-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-2(1H)-quinolinone 2-Hydroxypropanoic Acid; CHIR 258; TKI 258; (3Z)-4-Amino-5-fluoro-3-[5-(4-methyl-1-piperazinyl)-1,3-dihydro-2H-benzimidazol-2-ylidene]-2(3H)-quinolinone; (3E)-4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1,3-dihydrobenzimidazol-2-ylidene]quinolin-2-one; (3Z)-4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1,3-dihydrobenzimidazol-2-ylidene]quinolin-2-one; 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-1,3-benzodiazol-2-ylidene]-2,3-dihydroquinolin-2-one; 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-1,3-benzodiazol-2-yl]-1,2-dihydroquinolin-2-one

CAS No.: 405169-16-6

Compound CID: 135398510

Formula: C₂₁H₂₁FN₆

Formula Weight: 392.43

Specification

Stability: 3 years in powder form.

Storage: Storage at -20°C.

Applications: Dovitinib (TKI-258) is utilized in oncology research as a multi-targeted tyrosine kinase inhibitor to study the simultaneous blockage of VEGFR, FGFR, and PDGFR signaling in tumor angiogenesis and growth.